Valuation: Alkermes plc

Market Cap 6.92B 6.16B 5.71B 5.19B 9.74B 656B 9.9B 68.49B 26.93B 343B 25.95B 25.4B 1,095B P/E 2026 *
-81.5x
P/E 2027 * 74.6x
Enterprise Value 7.66B 6.83B 6.32B 5.75B 10.79B 726B 10.97B 75.86B 29.83B 380B 28.74B 28.14B 1,213B EV / Sales 2026 *
4.2x
EV / Sales 2027 * 3.9x
Free-Float
89.45%
Yield 2026 *
-
Yield 2027 * -
1 day+4.25%
1 week+6.73%
Current month+6.05%
1 month-0.97%
3 months-18.49%
6 months+24.44%
Current year+53.57%
1 week 38.98
Extreme 38.98
43.64
1 month 38.98
Extreme 38.98
44.79
Current year 27
Extreme 27
55.67
1 year 27
Extreme 27
55.67
3 years 22.01
Extreme 22.01
55.67
5 years 21.24
Extreme 21.24
55.67
10 years 11.98
Extreme 11.98
71.22
Manager TitleAgeSince
Chief Executive Officer 53 2026-07-31
Director of Finance/CFO 53 2025-09-14
Chief Tech/Sci/R&D Officer 58 2017-05-29
Director TitleAgeSince
Chairman 64 2011-08-31
Director/Board Member 53 2026-07-31
Director/Board Member 74 2016-05-25
Date Insider Type Main position Quantity % Market Cap. Importance
10/8/26 Exercice

Chief Financial Officer

22,397 0.0134%
10/7/26 Free

Director

25,237 0.0150%
10/2/26 Sell

Compliance Officer

-2,034 0.0012%
Change 5-day change 1-year change 3-year change Capi.($)
+4.25%+6.73%+42.00%+60.28% 6.92B
-1.33%+4.88%+54.50%+109.94% 1,120B
-0.69%-3.77%+31.35%+66.62% 616B
-0.96%+0.55%+23.13%+94.26% 504B
+0.24%+5.58%+33.98%+59.40% 367B
-1.59%-1.25%+69.39%+43.02% 360B
-0.40%+3.53%+19.17%+46.55% 288B
-0.37%+3.11%-1.26%+18.23% 258B
-1.75%+1.76%+42.21%+51.44% 234B
-2.00%+1.75%+24.64%+95.14% 194B
Average -0.46%+2.69%+33.91%+64.49% 394.78B
Weighted average by Cap. -0.98%+2.69%+37.90%+75.49%

Financials

2026 *2027 *
Net sales 1.82B 1.63B 1.51B 1.37B 2.57B 173B 2.61B 18.06B 7.1B 90.37B 6.84B 6.7B 289B 1.94B 1.73B 1.61B 1.46B 2.74B 184B 2.78B 19.25B 7.57B 96.32B 7.29B 7.14B 308B
Net income -92.03M -82.03M -75.99M -69.09M -130M -8.73B -132M -911M -358M -4.56B -345M -338M -14.58B 100M 89.47M 82.88M 75.36M 141M 9.52B 144M 994M 391M 4.97B 377M 369M 15.9B
Net Debt 744M 663M 614M 559M 1.05B 70.53B 1.07B 7.37B 2.9B 36.86B 2.79B 2.73B 118B 670M 597M 553M 503M 944M 63.52B 959M 6.64B 2.61B 33.2B 2.51B 2.46B 106B
Projected Income Statement - Annual - Alkermes plc
Logo Alkermes plc
Alkermes plc is an Ireland-based global biopharmaceutical company that seeks to develop medicines in the field of neuroscience. The Company has a portfolio of commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia, bipolar I disorder and narcolepsy. Its pipeline includes late-stage clinical candidates in development for narcolepsy and idiopathic hypersomnia, and orexin 2 receptor agonists in early clinical development for other neurological disorders, including attention-deficit hyperactivity disorder (ADHD) and fatigue associated with multiple sclerosis and Parkinson’s disease. The Company's pipeline includes Olanzapine and samidorphan, Alixorexton, ALKS 4510, ALKS 7290, and Valiloxybate. Its LUMRYZ (sodium oxybate) for extended-release oral suspension is a central nervous system depressant indicated for the treatment of cataplexy or excessive daytime sleepiness (EDS) in patients seven years of age and older with narcolepsy.
Employees
2,050
Date Price Change Volume
26-10-19 US$42.97 +4.25% 2,792,911
26-10-16 US$41.22 +2.79% 3,408,302
26-10-15 US$40.10 +2.61% 1,976,642
26-10-14 US$39.08 -1.64% 1,551,180
26-10-13 US$39.73 -1.32% 1,068,285
Trader
Investor
Global
Quality
ESG MSCI
A
MarketScreener Ratings - Alkermes plc
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
20
Last Close Price
42.97USD
Average target price
56.21USD
Spread / Average Target
+30.81%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Alkermes plc
  1. Stock Market
  2. Stocks
  3. ALKS Stock